CODEXIS, INC. (CDXS)
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Sector: Industrial Organic Chemicals
Industry: Biotechnology
Codexis, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 109.51M shares outstanding
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions.
Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening.
The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Leadership
Alison Moore, Ph.D.
Christos Richards
Cynthia Collins
David V. Smith
Employees
146
Country
US
Sector
Healthcare
Website
codexis.com
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| See Remarks | Sale | 6.3K | $8.6K | Oct 12, 2026 | |
| President and CEO | Sale | 6.3K | $8.6K | Oct 12, 2026 | |
| Director | Grant/Award | 66.3K | -- | Jun 17, 2026 | |
| Director | Grant/Award | 66.3K | -- | Jun 17, 2026 | |
| Director | Grant/Award | 66.3K | -- | Jun 17, 2026 | |
| Director | Grant/Award | 66.3K | -- | Jun 17, 2026 |
| Name | Shares | % | Source |
|---|---|---|---|
BlackRock, Inc. | 7.3M | 6.7% | 13F |
Opaleye Management Inc. | 6.8M | 6.2% | 13F |
Opaleye Management Inc. · also on 13F· joint filing· may incl. warrants· filed May 2026 | 6.8M | 6.2% | 13G |
Aberdeen Group plc | 6.8M | 6.2% | 13F |
Aberdeen Group plc · also on 13F· joint filing· may incl. warrants· filed Jul 2026 | 6.8M | 6.2% | 13G |
BlackRock, Inc. · also on 13F· may incl. warrants· filed Apr 2025 | 6.0M | 5.5% | 13G |
MILLENNIUM MANAGEMENT LLC | 5.5M | 5.1% | 13F |
Telemark Asset Management, LLC | 3.8M | 3.5% | 13F |
AMERIPRISE FINANCIAL INC | 3.8M | 3.5% | 13F |
Nantahala Capital Management, LLC | 3.6M | 3.3% | 13F |
Insiders
- Erbez GeorgiaSee Remarks
- MOORE ALISONPresident and CEO
- PARKER H STEWARTDirector
- De Vre RaymondDirector
- DILLY STEPHEN GEORGEDirector
- Martinborough EstherDirector
- Singhvi RahulDirector
- Smith David VDirector
- Richards ChristosDirector
- Collins CynthiaDirector
based on 109.51M shares outstanding
30d Avg
824.13K
60d Avg
852.88K
90d Avg
939.72K